Long-Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta-Analysis of Clinical Trials.

Endocrinol Diabetes MetabSep 1, 2026
Clinical ResearchEndocrinologyOpen access

Amir Abadi, Usra Ghanem, Hamid Ghanem et al.

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis evaluated the efficacy and safety of long-acting growth hormone (LAGH) versus daily growth hormone in children with growth hormone deficiency (CHD). Analyzing 18 randomized controlled trials with 3137 participants, the study found that weekly YPEG-rhGH 0.1 mg/kg/week significantly improved height velocity compared to daily Somatropin, while safety profiles varied among LAGH formulations.

Key findings

  • Weekly YPEG-rhGH 0.1 mg/kg/week showed a significantly higher height velocity compared to daily Somatropin (SMD: 5.02).
  • Lonapegsomatropin 0.24 mg/kg/week significantly increased IGF-1 SDS levels (SMD: 0.74 [0.36-1.12]).
  • Somatrogon significantly increased the risk of localized injection site erythema (RR: 10.55).
  • Overall treatment discontinuation rates did not differ significantly between LAGH formulations and daily therapy.

Why it matters

Understanding the comparative efficacy and safety of LAGH versus daily growth hormone is crucial for clinicians managing pediatric patients with growth hormone deficiency, as it informs treatment choices that can optimize patient outcomes.

Source

PubMed · PMID 42538635Free full text on PubMed Central

Published in Endocrinol Diabetes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.